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Abstract The reaction between human leukocyte elastase and 
soybean Bowman-Birk inhibitor has been studied. The inhibition 
was found to be due to slow tight binding of the inhibitor. The 
interaction of BBI with HLE was shown to involve two steps: the 
rapid formation of an initial £1 complex, with a A; of 28 n.YI, 
followed by a slow equilibrium conversion to a tighter-binding 
El* complex with a final K* of 2.3 nM. At pH 7.5 and 25°C, kon 
was 3.5 X10 4 M" 1 s"1 and koIt was 1.0 X10"
4 s"1. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The classical soybean Bowman-Birk proteinase inhibitor 
(BBI) is well known as an ancestor of the Bowman-Birk in-
hibitor family [1]. BBI is a protein of low molecular mass 
(8000 Da) . It has 71 amino acid residues, and contains 7 
disulphide bridges. Classical BBI, called a double-headed in-
hibitor, simultaneously inhibits trypsin via one reactive site, 
Lysi6-Ser17, and a-chymotrypsin via another, Leu43-Ser44 [ 1 -
3]. The ability of classical BBI to inhibit human granulocyte 
elastase (HLE) and cathepsin G reactions with synthetic and 
natural substrates has also been demonstrated [4-8]. H L E and 
human granulocyte cathepsin G are believed to be involved in 
the pathogenesis of a variety of diseases [9]. The high-effi-
ciency inhibitors of neutral leukocyte proteinases have been 
extensively studied because of their physiological significance, 
and potential therapeutic implications [10]. It should be noted, 
however, that the inhibition kinetics of H L E by the Bowman-
Birk inhibitors have not yet been studied. In this paper, the 
formal inhibition mechanisms were discriminated and the ki-
netic constants of interaction between BBI and H L E and dis-
sociation constants were determined. 
2. Materials and methods 
2.1. Materials 
ai-PI, MeOSuc-Ala-Ala-Pro-Val-pNA, HEPES, DMSO, p-mtro-
phenyl p'-guanidinobenzoate, Triton X-100 (Sigma, USA), bovine 
trypsin (Olaine Chemical Plant, Latvia) with 49% content of active 
sites (titrated with p-nitrophenyl //-guanidinobenzoate) [11]. HLE was 
purified as reported previously [5]. The classical BBI was isolated from 
Corresponding author. Fax: (7) (095) 939 09 97. 
Abbreviations: BBI, classical soybean Bowman-Birk proteinase in-
hibitor; HLE, human leukocyte elastase; ai-PI, di-proteinase 
inhibitor; MeO-Suc-Ala-Ala-Pro-Val-pNA, methoxysuccinyl-Ala-
Ala-Pro-Val-/)-nitroanilide; DMSO, dimethyl sulfoxide 
soybean cultivar VNIIS-2 according to a modified method of Odani 
and Ikenaka [2] described elsewhere [4], 
2.2. Active site titration 
Titration of HLE with standardized BBI and ai-PI revealed 93-
95% activity of enzyme. oii-Pl and BBI were quantified by direct 
titration with the active site-titrated trypsin, and were found to be 
47% (ai-PI) and 100% (BBI) active with respect to the total protein. 
2.3. Protein determination 
Protein was assayed according to Lowry et al. [12]. 
2.4. Kinetic procedure 
HLE activity measurements were made with MeO-Suc-Ala-Ala-
Pro-Val-pNA as a substrate, and its hydrolysis was followed by mon-
itoring the release of p-nitroaniline at 410 nm (6410 = 8800 M _ 1 cm - 1) 
(Shimadzu UV-265 FM recording spectrophotometer). A 1 ml cuvette 
(1 cm path length) containing 0.1 ml substrate (10~3 M in Me2SO) 
and 0.3-0.8 ml BBI in 0.1 M HEPES buffer, pH 7.5, containing 
0.005% Triton X-100 and 0.5 M NaCl, was incubated at 25°C for 
5-10 min in a jacketed holder in the spectrophotometer cell compart-
ment. Injection of 0.1 ml HLE solution initiated the reaction. The 
final concentrations of HLE, substrate and BBI were 4.3 nM, 0.1 
mM and 30-80 nM, respectively. 
2.5. Data analysis 
To assess the equilibrium and kinetic parameters of HLE-BBI in-
teraction, the method, offered for slow-binding inhibitors was used 
[13-15]. There are two basic mechanisms [14] (A and B) for slow 
inhibition of enzymes. 
Mechanism A: 
EI 
Mechanism B: 
E + S . ES ' E + P 
+ k2 
I 
ki k4 
k5 
EI , El* 
k,, 
The integrated equation (Eq. 1) describes product concentration in the 
presence of competitive slow-binding inhibitor which interacts with 
enzyme according to mechanism A or B, if [I]0 3> [E]0 and [P] <K [S]0 
[15]. 
P = vst+(v0—os)[l-exp(-kt)]/k (1) 
where P is the product concentration at any time (, v0 is the initial 
and Us is the final steady-state velocities, k is the apparent first-order 
rate constant for the establishment of the equilibrium between EI and 
EF. 
Progressive curves for HLE inhibition were fitted by non-linear 
regression to Eq. 1 using a Sigma Plot program for DOS (USA). 
Using the Marquardt method, the program performs simultaneous 
optimization of several parameters. As initial approaches for the three 
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empirical parameters v0, i)s and k, values calculated using the graphic 
method [16] were used. To verify the data obtained, the calculation 
was repeated with several other values of initial approximations. 
For mechanism A the following equations were used to calculate 
the association rate constant (kon) and dissociation rate constant (k0{{) 
[15]: 
k = koS + kon[I}J(l + [S}0/Km) (2) 
koB = kvs/v0 (3) 
The inhibition constant K* was calculated according to Eq. 4 from 
the final steady-state velocity data [15]. 
AT(1 + [Slo/AnO = [I]0/(t>c/us-l)-uS[E]>c (4) 
where uc is the control velocity in the absence of BBI. 
For mechanism B, the apparent first-order rate constant can be 
expressed as: 
k = k6 + fc6 i + [SL/*m + [i]0/*i. 
(5) 
where K^ is the constant of the first equilibrium (Ki = kjk?, [15]). 
The kinetic rate constants (k5, ks) and overall inhibition constant, 
K*, are defined in Eqs. 6-9 [15]. 
h = kvs/v0 (6) 
U o ■■ 
vs 
ME]0[S]0 
Km(l + [ll/KO + [S]„ 
^at[E]JS]0 
Am(l + P W ) + [S]„ 
h/(h + h) = K*/Ki 
3. Results and discussion 
(7) 
(8) 
(9) 
3.1. The inhibition parameters of HLE by BBI 
Fig. 1 shows the progressive inhibition of HLE by BBI in 
the presence of the substrate MeO-Suc-Ala-Ala-Pro-Val-pNA. 
The rate of substrate hydrolysis decreased from an initial rate 
(i)0) to a much slower steady-state rate (\>s) according to the 
first-order rate constant (k) Eq. 1. 
k is related to the kon and k0g by Eqs. 2 and 3. Thus, a 
replot of the k vs. [I]0 (Fig. 2) afforded these constants. Linear 
regression analysis provided accurate estimation of konl 
(\+[S\0/Km). The kon was calculated using [S]o=0.1 mM, 
JsTm = 0.055 mM and was equal to (3.5 ± 0.5) X 104 M"1 s"1. 
Linear regression analysis also provided the error on kon. As 
can be seen, the line intercepts the ordinate giving an accurate 
determination of kQs (see Eq. 2). In addition, the dissociation 
rate constant was calculated for each inhibitor concentration 
from Eq. 3. The k0s and its error were then computed from 
the individual values and were equal to (1.0 ± 0.2) X 10~4 s_1. 
The values of K* calculated from to Eq. 4 was equal to 
(2.0 ±0.5) nM. Taking into account the values of kinetic 
rate constants we may conclude that BBI is a slow-binding 
inhibitor of HLE. 
3.2. Mechanistic consideration of HLE inhibition by BBI 
An important problem in contemporary enzymology is the 
determination of the mechanism responsible for slow-binding 
inhibition. Slow-binding inhibitors are distinguished from 
their classical counterparts by diminished values of kon and 
k0it which are typically several orders of magnitude smaller 
than those of classical inhibitors. 
For mechanism A, it is assumed that the interaction of a 
competitive inhibitor with enzyme is slow because its concen-
tration is low and/or it encounters barriers for its binding at 
the site of substrate interaction. For mechanism B it is as-
sumed that there is an initial rapid interaction between the 
enzyme and competitive inhibitor to form El which then 
undergoes a slow conversion to a tighter-binding El* complex. 
In spite of the fact that the canonical mechanism of asso-
ciation of proteinases with their protein inhibitors was pro-
posed by Laskowski et al. [17] rather long ago, it was recently 
demonstrated [18-20] that every proteinase-inhibitor pair has 
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Fig. 1. Hydrolysis of MeOSucAlaAlaProValpNA by HLE in the presence of BBI. BBI concentrations in (nM): 0.0 (0), 30.0 (1), 40.0 (2), 50.0 
(3), 60.0 (4), 70.0 (5), 80.0 (6). [S]o = 0.1 mM, [E]0 = 4.3 nM, 0.1 M HEPES, pH 7.5, 0.5 M NaCl, 0.005% Triton X-100. 
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Fig. 2. Dependence of first-order rate constant for the approach to 
steady state on concentration of BBI. 
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Fig. 3. Plot of ln([P]s-[P]obs) against / for the inhibition of HLE by 
BBI. Data taken from curve 6 in Fig. 1. 
its own interaction peculiarities including various number of 
stages in this scheme. 
The progress curves for the inhibition of H L E by BBI were 
found to be biphasic, as illustrated in Fig. 1. In the absence of 
the inhibitor the steady-state velocity for the hydrolysis of 
MeO-Suc-Ala-Ala-Pro-Val-pNA was reached immediately. 
However, in the presence of BBI there is a slow decrease in 
both (initial and steady-state) substrate hydrolysis rates, 
which vary as a function of the inhibitor concentration. Anal-
ysis of these results can be used to derive the mechanism of 
HLE-BBI interaction. 
The characteristics i)o and k in Eq. 1 exhibit a different 
dependence on the inhibitor concentration for these two 
mechanisms. The initial velocity is independent of [I]0 for 
mechanism A, but decreases as the concentration of the in-
hibitor increases for mechanism B [14,15]. Linearity of plots 
of l/Uo vs. [I]0 (not shown) suggests that BBI binds to H L E 
according to mechanism B. Further, k varies as a linear func-
tion of [I]0 (Fig. 2) at BBI concentration up to 80 n M . F r o m a 
formal point of view this fact is consistent with mechanism A. 
The inhibition of H L E by BBI, and the inhibition of H L E [21] 
and human pancreatic elastase [22] by eglin C, are examples 
where it is problematic to distinguish whether the mechanism 
of slow inhibition belongs to the A or B type. Mechanism B 
seemed to be transformed into mechanism A because the 
range of inhibitor concentrations is insufficient to give satu-
ration of binding at the first step in mechanism B [14]. 
The kon value for association of BBI with H L E is 4 orders 
of magnitude lower than the rate constant for a bimolecular 
diffusion-controlled reaction. It may support the suggestion 
that the interaction between H L E and BBI occurs via a rap-
idly formed complex El followed by its slow rearrangement 
into El* (mechanism B). 
An additional method of analysis of the results was used for 
discrimination of the investigated mechanisms. For two-step 
interaction between the inhibitor and the enzyme, the forma-
tion of the reaction product as a function of time is: 
P U = [V\s-c,e-^-c2e (10) 
where [P]0bs is the product concentration actually observed, 
and [P]s is the product concentration when t approaches in-
finity [18]. 
It can be seen from Eq. 10 that a plot of ln([P]s—[P]0bs) 
against t should give a curve resolved into two straight lines 
with slopes of ri and r2 which are a combination of the rate 
constants. Such a plot for the course of MeOSucAlaAlaPro-
ValpNA hydrolysis by H L E in the presence of BBI, as shown 
in Fig. 3, suggested the formation of an intermediate for the 
binding of H L E with this inhibitor. 
Consequently, the measured rate constants kon and k0n are 
complex values consisting of microscopic terms. We calculated 
the rate constants of the elementary stages of the BBI and 
H L E interaction. The results are summarized in Table 1. Con-
trary to the general mechanism suggested by Laskowski, the 
Ki was found to be rather small and the stable complex El* 
had a dissociation constant that was only 1 order of magni-
tude lower than that of the initial complex EL A similar sit-
uation has been observed with human pancreatic elastase and 
eglin C where the initial inhibition constant, K\ was 0.3 u M 
[22]. The value of the ratio k5/Ki = 43x 104 M _ 1 s~4 was in 
good correspondence with that of kon for BBI-HLE interac-
tion. 
Although the biological and physicochemical properties of 
the classical soybean BBI have been well documented, crys-
tallographic analyses have not yet yielded its refined structure 
at high resolution. Nevertheless, Werner and Wemmer have 
reported the three-dimensional structure of BBI in solution 
[23] and identified the binding surface of BBI in contact 
with oc-chymotrypsin [24]. It should be noted that the anti-
Table 1 
Kinetic and inhibition constants for HLE-BBI interaction (pH 7.5, 25°C) 
Ki (nM) A? (nM) koa (XlO4 M" 1 s"1) ko{! ( X l O ^ s " 1 ) k5 (XlO"3 s"1) ks (XlO"4 s"1) 
28 ±0.5 
2.0 ±0.5 
2.3 ±0.5 
3.5 ±0.5 
fcs/ATi = 4.3 
1.0 ±0.2 
1.2 ±0.2 1.0 ±0.2 
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chymotryptic domain of the inhibitor is responsible for the 
interaction with H L E and cathepsin G. The surface of contact 
between BBI and a-chymotrypsin involved residues 39^18 of 
anti-chymotryptic domain (3-hairpin as well as residues 32, 33 
and 37 in the anti-chymotryptic domain loop of the inhibitor 
[24]. The conformation of the binding loop in the BBI-chymo-
trypsin complex is very similar to the canonical conformation 
observed in the crystal structure of the bound Bowman-Birk-
type trypsin inhibitor from mung bean [25], as well as the 
Kazal inhibitor family and the pota to inhibitor I family 
[24]. This can be the structural basis confirming that the in-
hibition of H L E by BBI occurs by the substrate-like s tandard 
Laskowski and Ka to mechanism [26]. This mechanism was 
multiply reported to hold for serine proteinase interaction 
with the above-mentioned families of protein inhibitors [27]. 
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